Hiltonol and Protamine-RNA stimulation induce an immune-activating transcriptome profile in cDC1s

preprint OA: closed
📄 Open PDF Full text JSON View at publisher

Abstract

Ex-vivo stimulation of dendritic cells (DCs) is a critical step in DC-based cancer immunotherapies. In humans, conventional type 1 dendritic cells (cDC1s) are a rare myeloid dendritic cell (mDC) subset that express BDCA-3 (CD141). cDC1s promote CD8 + T cell cross-priming against tumor antigens and are therefore being explored for use in immunotherapy. We evaluated the impact of ex-vivo stimulation on human peripheral blood cDC1s. In contrast to routine evaluation, which focuses on pre-defined surface maturation markers or soluble factors released from the activated cells, we investigated the impact of stimulation on the transcriptome using both RNA-sequencing (RNA-seq) and microarrays. Specifically, we analyzed the mRNA of cDC1s upon activation with two clinical-grade adjuvants, Hiltonol (poly IC, a TLR3 ligand) and protamine-stabilized RNA (pRNA, a TLR7/8 ligand) compared to unstimulated controls. Both RNA-seq and microarray analysis showed profound and similar effects of both Hiltonol and pRNA on the transcriptome of cDC1s. A gene ontology (GO) analysis suggested that these changes were mainly related to activation and maturation pathways, including induction of type-I interferon (IFN) and interleukin (IL)-12 transcription, while pathways related to adverse effects or cell damage did not appear to be affected. Combination of both reagents did not appear to have a synergistic effect, as the transcriptome changes were similar to those induced by each stimulus alone. Together, our results indicate that both adjuvants have comparable effects on cDC1 maturation within an immunogenic short-term culture as performed in immunotherapy.
Full text 2,040 characters · extracted from oa-doi-fallback · click to expand
Abstract Ex-vivo stimulation of dendritic cells (DCs) is a critical step in DC-based cancer immunotherapies. In humans, conventional type 1 dendritic cells (cDC1s) are a rare myeloid dendritic cell (mDC) subset that express BDCA-3 (CD141). cDC1s promote CD8+ T cell cross-priming against tumor antigens and are therefore being explored for use in immunotherapy. We evaluated the impact of ex-vivo stimulation on human peripheral blood cDC1s. In contrast to routine evaluation, which focuses on pre-defined surface maturation markers or soluble factors released from the activated cells, we investigated the impact of stimulation on the transcriptome using both RNA-sequencing (RNA-seq) and microarrays. Specifically, we analyzed the mRNA of cDC1s upon activation with two clinical-grade adjuvants, Hiltonol (poly IC, a TLR3 ligand) and protamine-stabilized RNA (pRNA, a TLR7/8 ligand) compared to unstimulated controls. Both RNA-seq and microarray analysis showed profound and similar effects of both Hiltonol and pRNA on the transcriptome of cDC1s. A gene ontology (GO) analysis suggested that these changes were mainly related to activation and maturation pathways, including induction of type-I interferon (IFN) and interleukin (IL)-12 transcription, while pathways related to adverse effects or cell damage did not appear to be affected. Combination of both reagents did not appear to have a synergistic effect, as the transcriptome changes were similar to those induced by each stimulus alone. Together, our results indicate that both adjuvants have comparable effects on cDC1 maturation within an immunogenic short-term culture as performed in immunotherapy. Competing Interest Statement The authors have declared no competing interest. List of abbreviations - cDC1 - conventional type 1 dendritic cell - cDC2 - conventional type 2 dendritic cell - DC - dendritic cell - GO - gene ontology - IFN - interferon - IL - interleukin - mDC - myeloid dendritic cell - pDC - plasmacytoid dendritic cell - PCoA - principal coordinates analysis

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00